|Bid||150.00 x 800|
|Ask||155.00 x 1000|
|Day's range||147.75 - 150.05|
|52-week range||105.56 - 175.91|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||21.52|
|Earnings date||28 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||5.64 (3.75%)|
|Ex-dividend date||14 Apr 2022|
|1y target est||164.45|
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
You know that you can count on them for leadership in their market and earnings growth. Here, I'll focus on three companies that stand out for their strong market positions: a biotech company and a medical device company that each dominate their fields, and a pharmaceutical player on the way to winning in market share. Vertex Pharmaceuticals (NASDAQ: VRTX) is the worldwide leader in cystic fibrosis (CF) treatment.
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.